Linda Watkins
Concepts (966)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neuralgia | 41 | 2026 | 141 | 11.340 |
Why?
| | Hyperalgesia | 71 | 2026 | 127 | 11.240 |
Why?
| | Toll-Like Receptor 4 | 46 | 2023 | 277 | 7.920 |
Why?
| | Pain | 62 | 2026 | 790 | 7.370 |
Why?
| | Microglia | 55 | 2024 | 289 | 6.690 |
Why?
| | Rats, Sprague-Dawley | 241 | 2026 | 2537 | 6.610 |
Why?
| | Spinal Cord | 50 | 2023 | 378 | 5.740 |
Why?
| | Rats | 283 | 2026 | 5586 | 5.620 |
Why?
| | Morphine | 41 | 2020 | 171 | 5.380 |
Why?
| | Neuroglia | 39 | 2015 | 177 | 4.570 |
Why?
| | Neuroimmunomodulation | 35 | 2025 | 67 | 4.360 |
Why?
| | Interleukin-10 | 23 | 2024 | 310 | 3.790 |
Why?
| | Analgesics, Opioid | 38 | 2019 | 1221 | 3.640 |
Why?
| | Animals | 365 | 2026 | 38107 | 3.160 |
Why?
| | Cytokines | 53 | 2024 | 2081 | 3.060 |
Why?
| | Chronic Pain | 10 | 2026 | 304 | 3.060 |
Why?
| | Interleukin-1beta | 33 | 2023 | 397 | 2.840 |
Why?
| | Interleukin-1 | 51 | 2011 | 960 | 2.780 |
Why?
| | Spinal Cord Injuries | 9 | 2021 | 238 | 2.680 |
Why?
| | Stress, Psychological | 60 | 2020 | 1171 | 2.670 |
Why?
| | Inflammation | 51 | 2024 | 2919 | 2.440 |
Why?
| | Sciatic Neuropathy | 13 | 2023 | 30 | 2.420 |
Why?
| | Behavior, Animal | 55 | 2020 | 531 | 2.400 |
Why?
| | Lymphocyte Antigen 96 | 12 | 2019 | 23 | 2.360 |
Why?
| | Lipopolysaccharides | 52 | 2023 | 861 | 2.350 |
Why?
| | Signal Transduction | 42 | 2025 | 5246 | 2.280 |
Why?
| | Genetic Therapy | 16 | 2024 | 303 | 2.220 |
Why?
| | Injections, Spinal | 39 | 2018 | 120 | 2.190 |
Why?
| | Pain Threshold | 23 | 2019 | 72 | 2.180 |
Why?
| | Central Nervous System | 13 | 2018 | 278 | 2.130 |
Why?
| | Hippocampus | 51 | 2020 | 989 | 2.100 |
Why?
| | Stress, Physiological | 45 | 2017 | 450 | 1.980 |
Why?
| | Pain Measurement | 37 | 2024 | 573 | 1.940 |
Why?
| | Narcotic Antagonists | 20 | 2020 | 210 | 1.910 |
Why?
| | Corticosterone | 33 | 2019 | 241 | 1.900 |
Why?
| | Inflammasomes | 9 | 2023 | 145 | 1.900 |
Why?
| | Inflammation Mediators | 16 | 2020 | 508 | 1.760 |
Why?
| | Analgesia | 13 | 2015 | 106 | 1.740 |
Why?
| | Encephalomyelitis, Autoimmune, Experimental | 5 | 2021 | 66 | 1.740 |
Why?
| | Naltrexone | 19 | 2023 | 114 | 1.700 |
Why?
| | Raphe Nuclei | 30 | 2014 | 112 | 1.680 |
Why?
| | Adenosine A2 Receptor Agonists | 4 | 2018 | 24 | 1.650 |
Why?
| | Male | 286 | 2026 | 73396 | 1.640 |
Why?
| | Disease Models, Animal | 46 | 2024 | 4580 | 1.570 |
Why?
| | HIV Envelope Protein gp120 | 12 | 2010 | 55 | 1.560 |
Why?
| | Vagus Nerve | 16 | 2001 | 92 | 1.490 |
Why?
| | Plasmids | 9 | 2024 | 373 | 1.450 |
Why?
| | Sciatic Nerve | 11 | 2024 | 63 | 1.430 |
Why?
| | Fear | 34 | 2020 | 373 | 1.420 |
Why?
| | Peripheral Nervous System Diseases | 10 | 2012 | 135 | 1.400 |
Why?
| | Naloxone | 16 | 2019 | 139 | 1.350 |
Why?
| | HMGB1 Protein | 12 | 2019 | 51 | 1.330 |
Why?
| | Prefrontal Cortex | 20 | 2018 | 339 | 1.330 |
Why?
| | Helplessness, Learned | 21 | 2012 | 67 | 1.290 |
Why?
| | Brain | 34 | 2024 | 2991 | 1.240 |
Why?
| | Immune System | 9 | 2026 | 181 | 1.230 |
Why?
| | Minocycline | 8 | 2017 | 23 | 1.210 |
Why?
| | Encephalitis | 10 | 2018 | 143 | 1.200 |
Why?
| | Receptors, Interleukin-1 | 17 | 2016 | 211 | 1.150 |
Why?
| | Neurons | 26 | 2022 | 1668 | 1.140 |
Why?
| | Electroshock | 61 | 2018 | 146 | 1.110 |
Why?
| | NLR Family, Pyrin Domain-Containing 3 Protein | 11 | 2023 | 167 | 1.110 |
Why?
| | Astrocytes | 10 | 2019 | 229 | 1.110 |
Why?
| | Glucocorticoids | 17 | 2019 | 536 | 1.090 |
Why?
| | Tumor Necrosis Factor-alpha | 27 | 2019 | 1224 | 1.080 |
Why?
| | Serotonin | 32 | 2020 | 297 | 1.070 |
Why?
| | Peripheral Nerve Injuries | 5 | 2023 | 39 | 1.060 |
Why?
| | Piperidines | 5 | 2018 | 225 | 1.060 |
Why?
| | Escape Reaction | 25 | 2014 | 55 | 1.050 |
Why?
| | Conditioning, Classical | 11 | 2020 | 120 | 1.040 |
Why?
| | Somatosensory Cortex | 3 | 2026 | 42 | 1.040 |
Why?
| | Toll-Like Receptor 2 | 7 | 2021 | 125 | 1.020 |
Why?
| | Nucleus Accumbens | 9 | 2019 | 135 | 1.010 |
Why?
| | Pain Management | 8 | 2021 | 421 | 1.010 |
Why?
| | Dependovirus | 2 | 2024 | 78 | 0.980 |
Why?
| | Central Nervous System Stimulants | 6 | 2019 | 183 | 0.960 |
Why?
| | Memory Disorders | 15 | 2020 | 198 | 0.940 |
Why?
| | Dose-Response Relationship, Drug | 41 | 2023 | 2022 | 0.880 |
Why?
| | Osteoarthritis | 2 | 2020 | 206 | 0.870 |
Why?
| | Conditioning, Operant | 13 | 2017 | 94 | 0.870 |
Why?
| | Escherichia coli Infections | 15 | 2014 | 125 | 0.860 |
Why?
| | Acute Pain | 1 | 2026 | 58 | 0.860 |
Why?
| | MicroRNAs | 3 | 2021 | 699 | 0.850 |
Why?
| | Low-Level Light Therapy | 1 | 2024 | 7 | 0.850 |
Why?
| | Dopamine | 8 | 2019 | 295 | 0.840 |
Why?
| | Circadian Rhythm | 8 | 2019 | 515 | 0.810 |
Why?
| | RNA, Messenger | 26 | 2017 | 2791 | 0.810 |
Why?
| | Ventral Tegmental Area | 4 | 2019 | 61 | 0.810 |
Why?
| | Glucuronides | 2 | 2014 | 18 | 0.800 |
Why?
| | Vagotomy | 15 | 2001 | 33 | 0.800 |
Why?
| | Alarmins | 5 | 2018 | 27 | 0.800 |
Why?
| | Fever | 11 | 2011 | 322 | 0.800 |
Why?
| | Posterior Horn Cells | 2 | 2019 | 10 | 0.790 |
Why?
| | Ganglia, Spinal | 6 | 2016 | 88 | 0.790 |
Why?
| | Psoriasis | 1 | 2024 | 110 | 0.780 |
Why?
| | Cocaine | 5 | 2023 | 162 | 0.760 |
Why?
| | Narcotics | 8 | 2014 | 57 | 0.760 |
Why?
| | Motor Activity | 21 | 2023 | 704 | 0.760 |
Why?
| | Physical Stimulation | 13 | 2014 | 68 | 0.750 |
Why?
| | Aging | 16 | 2021 | 1996 | 0.730 |
Why?
| | Morphine Derivatives | 2 | 2014 | 19 | 0.730 |
Why?
| | Analysis of Variance | 27 | 2018 | 1298 | 0.730 |
Why?
| | Pyridines | 7 | 2017 | 610 | 0.720 |
Why?
| | Chemokines, CX3C | 4 | 2005 | 10 | 0.710 |
Why?
| | Toll-Like Receptors | 6 | 2017 | 193 | 0.710 |
Why?
| | Drug Delivery Systems | 5 | 2024 | 377 | 0.690 |
Why?
| | Rats, Inbred F344 | 19 | 2018 | 266 | 0.690 |
Why?
| | Drug Tolerance | 6 | 2017 | 100 | 0.680 |
Why?
| | Methamphetamine | 3 | 2019 | 75 | 0.680 |
Why?
| | Time Factors | 42 | 2019 | 7109 | 0.670 |
Why?
| | Sciatica | 6 | 2012 | 8 | 0.660 |
Why?
| | Phenethylamines | 2 | 2018 | 16 | 0.650 |
Why?
| | Anti-Inflammatory Agents | 4 | 2018 | 474 | 0.640 |
Why?
| | Migraine Disorders | 3 | 2017 | 109 | 0.630 |
Why?
| | Amygdala | 10 | 2017 | 194 | 0.630 |
Why?
| | Interleukin-6 | 15 | 2014 | 784 | 0.620 |
Why?
| | Nociceptors | 8 | 2006 | 40 | 0.620 |
Why?
| | Nicotinic Agonists | 2 | 2012 | 140 | 0.610 |
Why?
| | Interleukin 1 Receptor Antagonist Protein | 14 | 2012 | 253 | 0.610 |
Why?
| | Anxiety | 15 | 2020 | 1125 | 0.610 |
Why?
| | Arthralgia | 1 | 2020 | 66 | 0.610 |
Why?
| | Laparotomy | 5 | 2020 | 111 | 0.590 |
Why?
| | Gene Expression Regulation | 19 | 2019 | 2599 | 0.580 |
Why?
| | Defecation | 1 | 2019 | 18 | 0.570 |
Why?
| | Multiple Sclerosis | 4 | 2021 | 435 | 0.570 |
Why?
| | Chronobiology Disorders | 1 | 2018 | 17 | 0.560 |
Why?
| | Substance-Related Disorders | 4 | 2024 | 1100 | 0.560 |
Why?
| | Receptors, Nicotinic | 2 | 2012 | 337 | 0.560 |
Why?
| | Adenosine | 2 | 2018 | 256 | 0.560 |
Why?
| | Reactive Oxygen Species | 2 | 2016 | 610 | 0.560 |
Why?
| | Neural Pathways | 13 | 2026 | 319 | 0.550 |
Why?
| | Spinal Cord Dorsal Horn | 3 | 2019 | 5 | 0.550 |
Why?
| | Synapses | 1 | 2022 | 448 | 0.540 |
Why?
| | Sex Characteristics | 5 | 2018 | 801 | 0.520 |
Why?
| | Neurons, Afferent | 4 | 2007 | 102 | 0.520 |
Why?
| | Immunity, Innate | 14 | 2019 | 844 | 0.520 |
Why?
| | Humans | 95 | 2026 | 146342 | 0.510 |
Why?
| | Neuroprotective Agents | 3 | 2015 | 146 | 0.510 |
Why?
| | Trigeminal Caudal Nucleus | 1 | 2017 | 1 | 0.510 |
Why?
| | Contusions | 1 | 2017 | 25 | 0.510 |
Why?
| | Ethanol | 5 | 2014 | 630 | 0.510 |
Why?
| | Proto-Oncogene Proteins c-fos | 14 | 2018 | 193 | 0.500 |
Why?
| | Facial Nerve Injuries | 1 | 2016 | 2 | 0.500 |
Why?
| | Membrane Proteins | 5 | 2010 | 1130 | 0.500 |
Why?
| | Reactive Nitrogen Species | 1 | 2016 | 16 | 0.490 |
Why?
| | Spinal Injuries | 1 | 2017 | 62 | 0.490 |
Why?
| | Macrophages | 11 | 2017 | 1532 | 0.490 |
Why?
| | Facial Nerve | 1 | 2016 | 35 | 0.490 |
Why?
| | Exercise Movement Techniques | 1 | 2016 | 6 | 0.490 |
Why?
| | Reward | 8 | 2015 | 242 | 0.480 |
Why?
| | Cells, Cultured | 17 | 2020 | 4118 | 0.480 |
Why?
| | Catheters, Indwelling | 3 | 2012 | 94 | 0.470 |
Why?
| | DNA | 6 | 2024 | 1421 | 0.470 |
Why?
| | NADPH Oxidases | 1 | 2016 | 122 | 0.470 |
Why?
| | Reaction Time | 17 | 2012 | 438 | 0.470 |
Why?
| | Cyclic AMP-Dependent Protein Kinases | 2 | 2014 | 125 | 0.470 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2018 | 233 | 0.460 |
Why?
| | Catheterization | 6 | 2007 | 179 | 0.460 |
Why?
| | Xanthines | 2 | 2014 | 22 | 0.460 |
Why?
| | Memory | 10 | 2018 | 298 | 0.450 |
Why?
| | Hindlimb | 3 | 2013 | 128 | 0.450 |
Why?
| | Excitatory Amino Acid Transporter 2 | 2 | 2016 | 14 | 0.440 |
Why?
| | Dorsal Raphe Nucleus | 4 | 2020 | 31 | 0.440 |
Why?
| | Microinjections | 19 | 2018 | 92 | 0.430 |
Why?
| | Liver | 6 | 2019 | 1864 | 0.430 |
Why?
| | Paralysis | 2 | 2015 | 69 | 0.430 |
Why?
| | Endotoxins | 5 | 2012 | 215 | 0.430 |
Why?
| | Xenobiotics | 1 | 2015 | 31 | 0.430 |
Why?
| | Resilience, Psychological | 3 | 2018 | 141 | 0.410 |
Why?
| | Gliosis | 4 | 2013 | 30 | 0.410 |
Why?
| | Chronic Disease | 11 | 2017 | 1827 | 0.400 |
Why?
| | T-Lymphocytes | 2 | 2021 | 2012 | 0.400 |
Why?
| | Fatigue | 1 | 2016 | 363 | 0.390 |
Why?
| | Neuropharmacology | 1 | 2013 | 4 | 0.390 |
Why?
| | Disease | 4 | 1999 | 97 | 0.380 |
Why?
| | Gonadal Steroid Hormones | 1 | 2014 | 143 | 0.380 |
Why?
| | Hot Temperature | 10 | 2009 | 396 | 0.380 |
Why?
| | Corticotropin-Releasing Hormone | 7 | 2005 | 72 | 0.380 |
Why?
| | Glucuronic Acid | 1 | 2013 | 30 | 0.380 |
Why?
| | Quinuclidines | 1 | 2012 | 11 | 0.380 |
Why?
| | Allergy and Immunology | 1 | 2013 | 42 | 0.370 |
Why?
| | HSP90 Heat-Shock Proteins | 2 | 2010 | 47 | 0.370 |
Why?
| | Injections, Intraperitoneal | 16 | 2009 | 115 | 0.360 |
Why?
| | Myeloid Differentiation Factor 88 | 5 | 2014 | 119 | 0.360 |
Why?
| | Models, Animal | 1 | 2014 | 387 | 0.360 |
Why?
| | Estradiol | 2 | 2014 | 517 | 0.350 |
Why?
| | Arthritis, Rheumatoid | 1 | 2021 | 1185 | 0.350 |
Why?
| | Facial Pain | 1 | 2012 | 12 | 0.350 |
Why?
| | Thiophenes | 1 | 2012 | 117 | 0.350 |
Why?
| | Exploratory Behavior | 7 | 2018 | 86 | 0.350 |
Why?
| | Protein Kinase C | 1 | 2013 | 250 | 0.350 |
Why?
| | Hyperesthesia | 3 | 2007 | 6 | 0.350 |
Why?
| | Mice | 24 | 2024 | 18297 | 0.350 |
Why?
| | Neuralgia, Postherpetic | 1 | 2012 | 40 | 0.350 |
Why?
| | NF-kappa B | 8 | 2019 | 674 | 0.340 |
Why?
| | Gram-Negative Bacterial Infections | 1 | 2011 | 50 | 0.330 |
Why?
| | Complement System Proteins | 2 | 2005 | 326 | 0.330 |
Why?
| | Brain-Derived Neurotrophic Factor | 6 | 2009 | 155 | 0.330 |
Why?
| | CD11b Antigen | 6 | 2010 | 60 | 0.330 |
Why?
| | Animals, Newborn | 14 | 2019 | 888 | 0.330 |
Why?
| | Avoidance Learning | 5 | 2018 | 64 | 0.320 |
Why?
| | Female | 36 | 2026 | 79499 | 0.320 |
Why?
| | Drug-Seeking Behavior | 2 | 2023 | 22 | 0.320 |
Why?
| | Ceftriaxone | 1 | 2010 | 21 | 0.310 |
Why?
| | Diet, High-Fat | 3 | 2017 | 267 | 0.310 |
Why?
| | Pyrazoles | 7 | 2017 | 517 | 0.310 |
Why?
| | Chemokines | 3 | 2021 | 217 | 0.310 |
Why?
| | Indolizines | 6 | 2017 | 13 | 0.310 |
Why?
| | Heterocyclic Compounds, 3-Ring | 1 | 2010 | 44 | 0.310 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 11 | 2012 | 974 | 0.310 |
Why?
| | Receptor, Adenosine A2A | 1 | 2009 | 23 | 0.300 |
Why?
| | Genetic Vectors | 4 | 2024 | 327 | 0.300 |
Why?
| | Up-Regulation | 4 | 2013 | 841 | 0.300 |
Why?
| | Morphinans | 3 | 2015 | 8 | 0.300 |
Why?
| | Self Administration | 5 | 2023 | 121 | 0.290 |
Why?
| | Constriction, Pathologic | 4 | 2016 | 240 | 0.290 |
Why?
| | Receptors, Opioid, mu | 6 | 2020 | 68 | 0.290 |
Why?
| | Respiratory Insufficiency | 2 | 2014 | 330 | 0.290 |
Why?
| | Formaldehyde | 6 | 2013 | 66 | 0.290 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 8 | 2012 | 846 | 0.290 |
Why?
| | Sialoglycoproteins | 8 | 2004 | 157 | 0.290 |
Why?
| | Meninges | 2 | 2006 | 54 | 0.290 |
Why?
| | Cell Line | 13 | 2019 | 2814 | 0.280 |
Why?
| | Neurotransmitter Agents | 2 | 2006 | 84 | 0.280 |
Why?
| | Behavior | 3 | 2006 | 90 | 0.280 |
Why?
| | Mice, Inbred BALB C | 7 | 2014 | 1244 | 0.280 |
Why?
| | Functional Laterality | 7 | 2016 | 242 | 0.280 |
Why?
| | Receptors, Tumor Necrosis Factor | 3 | 2004 | 162 | 0.270 |
Why?
| | HEK293 Cells | 6 | 2024 | 750 | 0.270 |
Why?
| | Injections, Subcutaneous | 9 | 2012 | 170 | 0.270 |
Why?
| | Endothelial Cells | 1 | 2014 | 876 | 0.270 |
Why?
| | Wakefulness | 1 | 2009 | 170 | 0.270 |
Why?
| | Glutamic Acid | 1 | 2010 | 255 | 0.270 |
Why?
| | Face | 1 | 2009 | 177 | 0.270 |
Why?
| | Parkinson Disease | 1 | 2014 | 614 | 0.270 |
Why?
| | Cerebral Cortex | 4 | 2018 | 485 | 0.270 |
Why?
| | Receptors, Opioid | 3 | 2011 | 21 | 0.270 |
Why?
| | Receptors, Immunologic | 3 | 2019 | 210 | 0.270 |
Why?
| | Microdialysis | 13 | 2012 | 56 | 0.260 |
Why?
| | Transgenes | 2 | 2024 | 178 | 0.260 |
Why?
| | Substance Withdrawal Syndrome | 5 | 2011 | 185 | 0.260 |
Why?
| | Molecular Dynamics Simulation | 3 | 2019 | 267 | 0.260 |
Why?
| | Receptors, Complement | 2 | 2005 | 126 | 0.260 |
Why?
| | Drug Design | 2 | 2010 | 180 | 0.260 |
Why?
| | Cues | 8 | 2013 | 326 | 0.260 |
Why?
| | Constriction | 3 | 2023 | 45 | 0.260 |
Why?
| | Clozapine | 2 | 2018 | 20 | 0.260 |
Why?
| | Biomedical Research | 2 | 2013 | 729 | 0.250 |
Why?
| | Alkaline Phosphatase | 3 | 2014 | 144 | 0.250 |
Why?
| | Nitric Oxide | 7 | 2019 | 883 | 0.250 |
Why?
| | Mycobacterium | 2 | 2018 | 102 | 0.250 |
Why?
| | Locomotion | 2 | 2018 | 102 | 0.250 |
Why?
| | Crotalid Venoms | 2 | 2004 | 30 | 0.250 |
Why?
| | Hypothalamus | 5 | 2008 | 161 | 0.250 |
Why?
| | Phospholipases A | 2 | 2004 | 97 | 0.250 |
Why?
| | Drug Administration Schedule | 7 | 2019 | 790 | 0.250 |
Why?
| | Chemokine CX3CL1 | 5 | 2008 | 25 | 0.250 |
Why?
| | Immunocompetence | 1 | 2006 | 46 | 0.240 |
Why?
| | Nerve Tissue Proteins | 5 | 2011 | 597 | 0.240 |
Why?
| | Immunohistochemistry | 17 | 2010 | 1712 | 0.240 |
Why?
| | Transfection | 3 | 2018 | 916 | 0.240 |
Why?
| | Dinoprostone | 4 | 2014 | 179 | 0.240 |
Why?
| | Cognition | 6 | 2018 | 1292 | 0.240 |
Why?
| | Limbic System | 3 | 2019 | 55 | 0.240 |
Why?
| | Citrates | 6 | 2006 | 41 | 0.230 |
Why?
| | Corpus Striatum | 3 | 2018 | 181 | 0.230 |
Why?
| | Cisterna Magna | 4 | 2013 | 8 | 0.230 |
Why?
| | Neuronal Plasticity | 3 | 2022 | 312 | 0.230 |
Why?
| | Hypothalamo-Hypophyseal System | 5 | 2012 | 204 | 0.230 |
Why?
| | Extinction, Psychological | 5 | 2023 | 93 | 0.230 |
Why?
| | Freezing Reaction, Cataleptic | 4 | 2013 | 27 | 0.230 |
Why?
| | Ketamine | 3 | 2018 | 144 | 0.230 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2006 | 178 | 0.230 |
Why?
| | Adaptation, Psychological | 2 | 2010 | 721 | 0.220 |
Why?
| | Paclitaxel | 1 | 2006 | 260 | 0.220 |
Why?
| | Bacterial Infections | 4 | 2009 | 247 | 0.220 |
Why?
| | Oxycodone | 3 | 2019 | 53 | 0.220 |
Why?
| | DNA-Binding Proteins | 3 | 2023 | 1468 | 0.220 |
Why?
| | Protein Binding | 9 | 2018 | 2244 | 0.220 |
Why?
| | Arousal | 6 | 2002 | 158 | 0.220 |
Why?
| | Aminoquinolines | 1 | 2024 | 18 | 0.210 |
Why?
| | Spinal Nerve Roots | 3 | 2012 | 30 | 0.210 |
Why?
| | Analgesics | 5 | 2020 | 230 | 0.210 |
Why?
| | Cyclooxygenase 2 | 4 | 2019 | 166 | 0.210 |
Why?
| | Models, Immunological | 1 | 2005 | 100 | 0.210 |
Why?
| | Infrared Rays | 1 | 2024 | 23 | 0.210 |
Why?
| | Nitric Oxide Synthase | 2 | 2004 | 233 | 0.210 |
Why?
| | Antibodies | 6 | 2018 | 400 | 0.210 |
Why?
| | Ligation | 3 | 2013 | 88 | 0.210 |
Why?
| | Administration, Cutaneous | 1 | 2024 | 128 | 0.210 |
Why?
| | Receptors, Tumor Necrosis Factor, Type I | 4 | 2008 | 79 | 0.210 |
Why?
| | Brain Mapping | 8 | 2018 | 541 | 0.210 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 5 | 2013 | 344 | 0.210 |
Why?
| | Vesiculovirus | 1 | 2024 | 17 | 0.210 |
Why?
| | Injections, Intraventricular | 13 | 2015 | 60 | 0.210 |
Why?
| | Models, Neurological | 2 | 2003 | 252 | 0.200 |
Why?
| | Central Nervous System Agents | 1 | 2003 | 7 | 0.200 |
Why?
| | Cholecystokinin | 4 | 2000 | 15 | 0.200 |
Why?
| | Body Fluids | 1 | 2004 | 70 | 0.200 |
Why?
| | Gap Junctions | 1 | 2004 | 68 | 0.200 |
Why?
| | Glial Fibrillary Acidic Protein | 8 | 2015 | 124 | 0.200 |
Why?
| | Transduction, Genetic | 1 | 2024 | 129 | 0.200 |
Why?
| | Carrier Proteins | 5 | 2015 | 728 | 0.200 |
Why?
| | Lumbosacral Region | 4 | 2013 | 58 | 0.200 |
Why?
| | Norepinephrine | 5 | 2005 | 201 | 0.190 |
Why?
| | Neural Inhibition | 2 | 2010 | 186 | 0.190 |
Why?
| | Central Nervous System Diseases | 2 | 2017 | 73 | 0.190 |
Why?
| | Animals, Genetically Modified | 1 | 2024 | 248 | 0.190 |
Why?
| | Mice, Knockout | 5 | 2021 | 3125 | 0.190 |
Why?
| | Antigens, CD | 4 | 2017 | 560 | 0.190 |
Why?
| | Mifepristone | 6 | 2019 | 45 | 0.190 |
Why?
| | Adrenalectomy | 10 | 2014 | 68 | 0.190 |
Why?
| | Enzyme Inhibitors | 6 | 2007 | 823 | 0.190 |
Why?
| | Pituitary Gland | 6 | 2004 | 148 | 0.190 |
Why?
| | Freund's Adjuvant | 2 | 2013 | 17 | 0.190 |
Why?
| | Learning | 7 | 2018 | 446 | 0.190 |
Why?
| | Receptors, Glucocorticoid | 5 | 2016 | 132 | 0.180 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 2 | 2015 | 213 | 0.180 |
Why?
| | Gene Expression | 8 | 2020 | 1463 | 0.180 |
Why?
| | Illness Behavior | 2 | 2014 | 8 | 0.180 |
Why?
| | Brain Chemistry | 3 | 2004 | 122 | 0.180 |
Why?
| | Myelin-Oligodendrocyte Glycoprotein | 2 | 2021 | 53 | 0.180 |
Why?
| | Fibroblast Growth Factor 2 | 3 | 2007 | 93 | 0.180 |
Why?
| | Random Allocation | 6 | 2016 | 366 | 0.180 |
Why?
| | Opioid-Related Disorders | 5 | 2017 | 634 | 0.180 |
Why?
| | Synaptic Transmission | 4 | 2010 | 294 | 0.180 |
Why?
| | Caspase 1 | 3 | 2020 | 145 | 0.180 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 3 | 2016 | 263 | 0.180 |
Why?
| | Social Behavior | 8 | 2018 | 279 | 0.180 |
Why?
| | Spleen | 7 | 2014 | 503 | 0.170 |
Why?
| | Cocaine-Related Disorders | 1 | 2023 | 132 | 0.170 |
Why?
| | Psychoneuroimmunology | 3 | 2002 | 9 | 0.170 |
Why?
| | Molecular Targeted Therapy | 2 | 2017 | 447 | 0.170 |
Why?
| | Immunity, Cellular | 2 | 2002 | 277 | 0.170 |
Why?
| | Cognitive Dysfunction | 2 | 2018 | 481 | 0.170 |
Why?
| | Affect | 3 | 2018 | 318 | 0.170 |
Why?
| | GABA Antagonists | 4 | 2010 | 35 | 0.170 |
Why?
| | Indoles | 4 | 2013 | 511 | 0.170 |
Why?
| | Tail | 11 | 2007 | 29 | 0.160 |
Why?
| | alpha7 Nicotinic Acetylcholine Receptor | 2 | 2012 | 105 | 0.160 |
Why?
| | Central Nervous System Depressants | 2 | 2014 | 83 | 0.160 |
Why?
| | Zymosan | 4 | 2005 | 39 | 0.160 |
Why?
| | 8-Hydroxy-2-(di-n-propylamino)tetralin | 4 | 2009 | 9 | 0.160 |
Why?
| | Touch | 3 | 2013 | 38 | 0.160 |
Why?
| | Receptors, HIV | 3 | 2004 | 23 | 0.160 |
Why?
| | Cell Communication | 3 | 2009 | 327 | 0.160 |
Why?
| | Fentanyl | 2 | 2019 | 126 | 0.160 |
Why?
| | Neurogenesis | 1 | 2022 | 158 | 0.160 |
Why?
| | Dexamethasone | 5 | 2012 | 368 | 0.160 |
Why?
| | Body Temperature | 5 | 2002 | 228 | 0.160 |
Why?
| | Drug Interactions | 6 | 2008 | 405 | 0.160 |
Why?
| | Receptors, Cytokine | 3 | 2004 | 36 | 0.160 |
Why?
| | Models, Molecular | 5 | 2012 | 1574 | 0.160 |
Why?
| | Convulsants | 4 | 1998 | 8 | 0.160 |
Why?
| | Specific Pathogen-Free Organisms | 5 | 2004 | 58 | 0.150 |
Why?
| | AIDS Dementia Complex | 1 | 2000 | 49 | 0.150 |
Why?
| | Drug Synergism | 4 | 2015 | 354 | 0.150 |
Why?
| | Thoracic Vertebrae | 2 | 2019 | 90 | 0.150 |
Why?
| | Carbolines | 4 | 1998 | 35 | 0.150 |
Why?
| | Lithium Chloride | 3 | 1994 | 14 | 0.150 |
Why?
| | Skin | 1 | 2024 | 701 | 0.150 |
Why?
| | Dogs | 2 | 2020 | 517 | 0.150 |
Why?
| | Lovastatin | 1 | 2019 | 37 | 0.150 |
Why?
| | Receptors, Corticotropin-Releasing Hormone | 4 | 2004 | 30 | 0.150 |
Why?
| | Antibody Formation | 6 | 2002 | 290 | 0.150 |
Why?
| | Hemocyanins | 8 | 2003 | 61 | 0.150 |
Why?
| | Microfilament Proteins | 3 | 2016 | 136 | 0.150 |
Why?
| | Immunization | 4 | 2018 | 376 | 0.140 |
Why?
| | Thalamus | 2 | 2018 | 134 | 0.140 |
Why?
| | CLOCK Proteins | 1 | 2018 | 9 | 0.140 |
Why?
| | Tumor Necrosis Factor Decoy Receptors | 3 | 2004 | 8 | 0.140 |
Why?
| | Diaphragm | 5 | 2001 | 45 | 0.140 |
Why?
| | Purinergic P1 Receptor Agonists | 1 | 2018 | 7 | 0.140 |
Why?
| | Pituitary-Adrenal System | 5 | 2004 | 169 | 0.140 |
Why?
| | Receptors, Purinergic P1 | 1 | 2018 | 30 | 0.140 |
Why?
| | Motor Disorders | 1 | 2018 | 17 | 0.140 |
Why?
| | Calcium-Binding Proteins | 3 | 2016 | 221 | 0.140 |
Why?
| | Medulla Oblongata | 2 | 2014 | 36 | 0.140 |
Why?
| | Restraint, Physical | 11 | 2007 | 70 | 0.140 |
Why?
| | Receptor, Serotonin, 5-HT1A | 2 | 2011 | 37 | 0.140 |
Why?
| | Recombinant Proteins | 8 | 2005 | 1361 | 0.140 |
Why?
| | Gene Knockdown Techniques | 1 | 2019 | 335 | 0.140 |
Why?
| | Designer Drugs | 1 | 2018 | 7 | 0.140 |
Why?
| | Mice, Inbred C57BL | 4 | 2021 | 6034 | 0.140 |
Why?
| | Molecular Docking Simulation | 2 | 2018 | 121 | 0.140 |
Why?
| | Septal Nuclei | 2 | 2011 | 24 | 0.140 |
Why?
| | Maze Learning | 2 | 2016 | 106 | 0.140 |
Why?
| | Body Weight | 4 | 2018 | 968 | 0.130 |
Why?
| | Abdomen | 1 | 1999 | 142 | 0.130 |
Why?
| | Bacterial Vaccines | 1 | 2018 | 63 | 0.130 |
Why?
| | Sleep Disorders, Circadian Rhythm | 1 | 2018 | 55 | 0.130 |
Why?
| | Transcortin | 4 | 1999 | 14 | 0.130 |
Why?
| | Cyclooxygenase 1 | 2 | 2008 | 27 | 0.130 |
Why?
| | Statistics, Nonparametric | 1 | 2018 | 426 | 0.130 |
Why?
| | Probiotics | 1 | 2018 | 64 | 0.130 |
Why?
| | Excitatory Amino Acid Antagonists | 1 | 2018 | 108 | 0.130 |
Why?
| | Receptors, Purinergic P2X7 | 1 | 2017 | 12 | 0.130 |
Why?
| | Brain Injuries | 2 | 2013 | 499 | 0.130 |
Why?
| | Muscimol | 7 | 2011 | 23 | 0.130 |
Why?
| | Amphetamine | 3 | 2010 | 37 | 0.130 |
Why?
| | Nitrites | 2 | 2016 | 85 | 0.130 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2020 | 457 | 0.130 |
Why?
| | Acoustic Stimulation | 5 | 2011 | 325 | 0.130 |
Why?
| | Methadone | 2 | 2010 | 130 | 0.130 |
Why?
| | Biomarkers | 5 | 2012 | 4340 | 0.130 |
Why?
| | Taste | 3 | 2008 | 237 | 0.130 |
Why?
| | Facial Nucleus | 1 | 2016 | 1 | 0.130 |
Why?
| | Rats, Inbred Strains | 7 | 2017 | 316 | 0.130 |
Why?
| | Macrophage Activation | 1 | 2018 | 182 | 0.120 |
Why?
| | Receptors, Purinergic P2X5 | 1 | 2016 | 3 | 0.120 |
Why?
| | Activating Transcription Factor 3 | 1 | 2016 | 4 | 0.120 |
Why?
| | Habenula | 1 | 2016 | 13 | 0.120 |
Why?
| | Dura Mater | 1 | 2017 | 41 | 0.120 |
Why?
| | Toll-Like Receptor 5 | 1 | 2016 | 18 | 0.120 |
Why?
| | p21-Activated Kinases | 1 | 2016 | 13 | 0.120 |
Why?
| | Spatial Memory | 1 | 2016 | 28 | 0.120 |
Why?
| | Down-Regulation | 2 | 2017 | 614 | 0.120 |
Why?
| | Models, Biological | 3 | 2017 | 1761 | 0.120 |
Why?
| | CX3C Chemokine Receptor 1 | 3 | 2004 | 19 | 0.120 |
Why?
| | Guanidines | 3 | 2003 | 39 | 0.120 |
Why?
| | Radiculopathy | 2 | 2014 | 38 | 0.120 |
Why?
| | Arrhythmias, Cardiac | 2 | 2018 | 358 | 0.120 |
Why?
| | Brain Ischemia | 2 | 2018 | 362 | 0.120 |
Why?
| | Neurogenic Inflammation | 1 | 2016 | 2 | 0.120 |
Why?
| | Hydrazones | 3 | 2003 | 26 | 0.120 |
Why?
| | Cell Count | 9 | 2009 | 315 | 0.120 |
Why?
| | Flumazenil | 1 | 1995 | 8 | 0.110 |
Why?
| | Analgesics, Non-Narcotic | 1 | 1997 | 129 | 0.110 |
Why?
| | Anilides | 3 | 2003 | 83 | 0.110 |
Why?
| | Nociception | 2 | 2015 | 17 | 0.110 |
Why?
| | Life Expectancy | 1 | 2016 | 72 | 0.110 |
Why?
| | Physical Conditioning, Animal | 3 | 2014 | 243 | 0.110 |
Why?
| | Isomerism | 2 | 2018 | 55 | 0.110 |
Why?
| | Reflex, Abnormal | 1 | 2014 | 8 | 0.110 |
Why?
| | Autoimmunity | 1 | 2021 | 925 | 0.110 |
Why?
| | Excitatory Amino Acids | 1 | 1994 | 7 | 0.110 |
Why?
| | Antibodies, Neutralizing | 1 | 2018 | 348 | 0.110 |
Why?
| | NG-Nitroarginine Methyl Ester | 2 | 2005 | 48 | 0.110 |
Why?
| | Polyethylene Glycols | 2 | 2010 | 650 | 0.110 |
Why?
| | Picrotoxin | 5 | 2018 | 12 | 0.110 |
Why?
| | Mice, Inbred C3H | 1 | 2015 | 252 | 0.110 |
Why?
| | Drug Administration Routes | 2 | 2012 | 41 | 0.110 |
Why?
| | Dopamine Plasma Membrane Transport Proteins | 1 | 2015 | 59 | 0.110 |
Why?
| | Neuropeptides | 1 | 1994 | 76 | 0.100 |
Why?
| | Body Temperature Regulation | 2 | 2009 | 106 | 0.100 |
Why?
| | Memory, Long-Term | 3 | 2020 | 12 | 0.100 |
Why?
| | Receptors, GABA-A | 1 | 1995 | 138 | 0.100 |
Why?
| | Morphine Dependence | 2 | 2011 | 5 | 0.100 |
Why?
| | Circadian Clocks | 1 | 2014 | 59 | 0.100 |
Why?
| | Thiazolidinediones | 1 | 2015 | 142 | 0.100 |
Why?
| | Immunosuppressive Agents | 2 | 2013 | 829 | 0.100 |
Why?
| | PPAR gamma | 1 | 2015 | 182 | 0.100 |
Why?
| | Host-Pathogen Interactions | 3 | 2012 | 366 | 0.100 |
Why?
| | Phosphodiesterase Inhibitors | 1 | 2014 | 73 | 0.100 |
Why?
| | Nervous System | 1 | 1994 | 68 | 0.100 |
Why?
| | Brain Stem | 2 | 2010 | 101 | 0.100 |
Why?
| | Leukocytes, Mononuclear | 1 | 2016 | 585 | 0.100 |
Why?
| | Phosphorylation | 3 | 2012 | 1724 | 0.100 |
Why?
| | Glucose | 1 | 2019 | 1053 | 0.100 |
Why?
| | Escherichia coli | 5 | 2016 | 832 | 0.100 |
Why?
| | Cell Death | 1 | 2015 | 379 | 0.100 |
Why?
| | B-Lymphocytes | 2 | 2012 | 887 | 0.100 |
Why?
| | Pentamidine | 1 | 2012 | 3 | 0.090 |
Why?
| | Interleukins | 2 | 2006 | 248 | 0.090 |
Why?
| | Running | 2 | 2017 | 235 | 0.090 |
Why?
| | Interpersonal Relations | 1 | 2016 | 387 | 0.090 |
Why?
| | Swimming | 1 | 2013 | 54 | 0.090 |
Why?
| | Heroin | 1 | 2013 | 30 | 0.090 |
Why?
| | Viral Matrix Proteins | 1 | 2012 | 28 | 0.090 |
Why?
| | Rifampin | 1 | 2013 | 80 | 0.090 |
Why?
| | Recovery of Function | 1 | 2017 | 725 | 0.090 |
Why?
| | Rats, Wistar | 4 | 2016 | 451 | 0.090 |
Why?
| | Serotonin Receptor Agonists | 4 | 2013 | 27 | 0.090 |
Why?
| | Adrenocorticotropic Hormone | 6 | 2004 | 145 | 0.090 |
Why?
| | Blood-Brain Barrier | 2 | 2009 | 169 | 0.090 |
Why?
| | Oncogene Proteins v-fos | 4 | 2015 | 5 | 0.090 |
Why?
| | Receptors, Cholecystokinin | 1 | 1992 | 9 | 0.090 |
Why?
| | Organ Culture Techniques | 2 | 2010 | 150 | 0.090 |
Why?
| | Cytoskeletal Proteins | 2 | 2010 | 146 | 0.090 |
Why?
| | Lipopeptides | 1 | 2012 | 17 | 0.090 |
Why?
| | Somatostatin | 1 | 1992 | 54 | 0.090 |
Why?
| | Cerebral Ventricles | 1 | 1992 | 56 | 0.090 |
Why?
| | DNA, Complementary | 2 | 2010 | 269 | 0.090 |
Why?
| | Structure-Activity Relationship | 3 | 2019 | 563 | 0.090 |
Why?
| | Association Learning | 4 | 2007 | 69 | 0.090 |
Why?
| | Behavior, Addictive | 1 | 2013 | 90 | 0.090 |
Why?
| | Cell Line, Transformed | 1 | 2012 | 137 | 0.090 |
Why?
| | Tetracyclines | 1 | 2012 | 16 | 0.090 |
Why?
| | Antigens | 3 | 2003 | 350 | 0.090 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 1 | 2012 | 170 | 0.090 |
Why?
| | Tissue Distribution | 2 | 2016 | 334 | 0.090 |
Why?
| | Lipopolysaccharide Receptors | 1 | 2012 | 88 | 0.090 |
Why?
| | Herpesvirus 4, Human | 1 | 2012 | 172 | 0.090 |
Why?
| | DNA Primers | 2 | 2010 | 487 | 0.090 |
Why?
| | Gene Transfer Techniques | 2 | 2010 | 185 | 0.090 |
Why?
| | Adaptor Proteins, Signal Transducing | 2 | 2017 | 429 | 0.080 |
Why?
| | Mice, Inbred CBA | 1 | 2011 | 56 | 0.080 |
Why?
| | Phenylurea Compounds | 1 | 1992 | 122 | 0.080 |
Why?
| | Macrophages, Peritoneal | 1 | 2011 | 89 | 0.080 |
Why?
| | Vasodilation | 1 | 2014 | 519 | 0.080 |
Why?
| | Sensation | 1 | 1991 | 56 | 0.080 |
Why?
| | Superoxides | 2 | 2022 | 198 | 0.080 |
Why?
| | Peptide Fragments | 3 | 2011 | 693 | 0.080 |
Why?
| | Rats, Inbred BN | 4 | 2012 | 56 | 0.080 |
Why?
| | Endocrine Glands | 1 | 1990 | 14 | 0.080 |
Why?
| | Stroke | 2 | 2018 | 1287 | 0.080 |
Why?
| | Heart Arrest | 1 | 2015 | 411 | 0.080 |
Why?
| | Phenylephrine | 1 | 1990 | 74 | 0.080 |
Why?
| | GABA Agonists | 4 | 2008 | 24 | 0.080 |
Why?
| | Muscles | 1 | 1991 | 330 | 0.080 |
Why?
| | Prostaglandins | 2 | 2007 | 94 | 0.080 |
Why?
| | Drug Combinations | 2 | 2009 | 400 | 0.080 |
Why?
| | Food Preferences | 2 | 2008 | 126 | 0.080 |
Why?
| | Benzylidene Compounds | 1 | 2010 | 23 | 0.080 |
Why?
| | Sphingolipids | 1 | 2010 | 83 | 0.080 |
Why?
| | Computational Biology | 2 | 2012 | 678 | 0.080 |
Why?
| | Protein Interaction Mapping | 1 | 2010 | 105 | 0.080 |
Why?
| | Receptor, Serotonin, 5-HT2C | 1 | 2009 | 14 | 0.080 |
Why?
| | Anti-Infective Agents | 1 | 2012 | 234 | 0.080 |
Why?
| | Immunologic Factors | 1 | 2012 | 244 | 0.080 |
Why?
| | Mitochondria | 1 | 2016 | 997 | 0.080 |
Why?
| | Receptors, Interleukin-1 Type I | 2 | 2011 | 25 | 0.080 |
Why?
| | Histamine | 1 | 2009 | 52 | 0.080 |
Why?
| | Stress Disorders, Traumatic | 1 | 2009 | 25 | 0.080 |
Why?
| | Bradykinin | 1 | 2009 | 49 | 0.070 |
Why?
| | Dimethyl Sulfoxide | 1 | 2009 | 42 | 0.070 |
Why?
| | Afferent Pathways | 3 | 2005 | 46 | 0.070 |
Why?
| | Infusion Pumps | 1 | 2009 | 33 | 0.070 |
Why?
| | Hypnotics and Sedatives | 1 | 2012 | 223 | 0.070 |
Why?
| | Eating | 3 | 2000 | 386 | 0.070 |
Why?
| | Motor Neurons | 1 | 2012 | 239 | 0.070 |
Why?
| | Injections, Intravenous | 3 | 1998 | 197 | 0.070 |
Why?
| | Amnesia, Retrograde | 2 | 2006 | 6 | 0.070 |
Why?
| | Perception | 1 | 1992 | 373 | 0.070 |
Why?
| | Antigens, Differentiation, Myelomonocytic | 1 | 2009 | 66 | 0.070 |
Why?
| | Toll-Like Receptor 9 | 1 | 2009 | 37 | 0.070 |
Why?
| | Lactams, Macrocyclic | 1 | 2009 | 51 | 0.070 |
Why?
| | Benzoquinones | 1 | 2009 | 46 | 0.070 |
Why?
| | Immunoglobulin M | 4 | 2001 | 284 | 0.070 |
Why?
| | Central Nervous System Infections | 1 | 2009 | 34 | 0.070 |
Why?
| | Disease Susceptibility | 1 | 2011 | 339 | 0.070 |
Why?
| | CpG Islands | 1 | 2009 | 175 | 0.070 |
Why?
| | Anxiety Disorders | 1 | 2012 | 354 | 0.070 |
Why?
| | Spatial Behavior | 1 | 2008 | 24 | 0.070 |
Why?
| | Neoplasms | 2 | 2010 | 2954 | 0.070 |
Why?
| | High-Throughput Screening Assays | 1 | 2010 | 179 | 0.070 |
Why?
| | Age Factors | 7 | 2010 | 3347 | 0.070 |
Why?
| | RAW 264.7 Cells | 2 | 2019 | 51 | 0.070 |
Why?
| | Cognition Disorders | 1 | 2012 | 559 | 0.070 |
Why?
| | Sex Factors | 2 | 2012 | 2107 | 0.070 |
Why?
| | Ligands | 1 | 2010 | 678 | 0.070 |
Why?
| | beta-Adrenergic Receptor Kinases | 1 | 2007 | 4 | 0.060 |
Why?
| | RNA, Antisense | 1 | 2007 | 18 | 0.060 |
Why?
| | Safety | 3 | 2008 | 347 | 0.060 |
Why?
| | Drugs, Investigational | 1 | 2007 | 31 | 0.060 |
Why?
| | Mice, Transgenic | 1 | 2012 | 2134 | 0.060 |
Why?
| | Immune Tolerance | 1 | 2009 | 386 | 0.060 |
Why?
| | Cholesterol | 2 | 2003 | 411 | 0.060 |
Why?
| | Foreign-Body Reaction | 1 | 2007 | 34 | 0.060 |
Why?
| | Evidence-Based Medicine | 1 | 2010 | 731 | 0.060 |
Why?
| | GABA-A Receptor Agonists | 3 | 2011 | 17 | 0.060 |
Why?
| | Receptors, Serotonin | 2 | 1997 | 33 | 0.060 |
Why?
| | Mental Disorders | 1 | 2016 | 1148 | 0.060 |
Why?
| | Stereoisomerism | 2 | 2019 | 102 | 0.060 |
Why?
| | Enzyme Activation | 2 | 2005 | 759 | 0.060 |
Why?
| | Mutation | 2 | 2015 | 4093 | 0.060 |
Why?
| | Injections, Intramuscular | 1 | 2006 | 140 | 0.060 |
Why?
| | Genes, MHC Class II | 1 | 2006 | 77 | 0.060 |
Why?
| | Oxidative Stress | 1 | 2013 | 1369 | 0.060 |
Why?
| | Antibodies, Blocking | 1 | 2005 | 38 | 0.060 |
Why?
| | Sodium Chloride | 1 | 2006 | 138 | 0.060 |
Why?
| | Peptides | 2 | 2009 | 992 | 0.060 |
Why?
| | Histocompatibility Antigens | 1 | 2006 | 102 | 0.060 |
Why?
| | Centrifugation | 1 | 2005 | 29 | 0.060 |
Why?
| | Electric Stimulation | 4 | 2011 | 273 | 0.060 |
Why?
| | Transcriptome | 1 | 2012 | 1068 | 0.060 |
Why?
| | Blotting, Western | 3 | 2013 | 1177 | 0.060 |
Why?
| | Cell Survival | 3 | 2019 | 1105 | 0.060 |
Why?
| | Caspase Inhibitors | 1 | 2005 | 81 | 0.060 |
Why?
| | Reinforcement Schedule | 3 | 2017 | 25 | 0.060 |
Why?
| | Hypoglycemic Agents | 1 | 2015 | 1412 | 0.050 |
Why?
| | Complement C5a | 1 | 2005 | 54 | 0.050 |
Why?
| | Hormone Antagonists | 3 | 2016 | 32 | 0.050 |
Why?
| | Complement C3a | 1 | 2005 | 40 | 0.050 |
Why?
| | Adrenal Glands | 2 | 2018 | 77 | 0.050 |
Why?
| | Carbenoxolone | 1 | 2004 | 1 | 0.050 |
Why?
| | Glycyrrhizic Acid | 1 | 2004 | 3 | 0.050 |
Why?
| | Computer Simulation | 1 | 2009 | 1014 | 0.050 |
Why?
| | In Vitro Techniques | 1 | 2006 | 1041 | 0.050 |
Why?
| | Anti-Ulcer Agents | 1 | 2004 | 12 | 0.050 |
Why?
| | Electric Countershock | 2 | 1984 | 126 | 0.050 |
Why?
| | Nerve Compression Syndromes | 1 | 2004 | 23 | 0.050 |
Why?
| | Stress, Mechanical | 1 | 2007 | 497 | 0.050 |
Why?
| | Cell Separation | 1 | 2005 | 300 | 0.050 |
Why?
| | Nitric Oxide Synthase Type I | 1 | 2004 | 31 | 0.050 |
Why?
| | Postoperative Complications | 2 | 2012 | 3034 | 0.050 |
Why?
| | Epilepsy | 1 | 2009 | 400 | 0.050 |
Why?
| | Receptors, Adrenergic, alpha-1 | 1 | 2004 | 45 | 0.050 |
Why?
| | Adenoviridae | 1 | 2005 | 197 | 0.050 |
Why?
| | Catalase | 1 | 2004 | 133 | 0.050 |
Why?
| | Clinical Trials as Topic | 1 | 2009 | 1064 | 0.050 |
Why?
| | N-Methylaspartate | 1 | 2004 | 43 | 0.050 |
Why?
| | Binding Sites | 2 | 2018 | 1309 | 0.050 |
Why?
| | Hypothermia | 1 | 2004 | 53 | 0.050 |
Why?
| | Peripheral Nervous System | 1 | 2003 | 20 | 0.050 |
Why?
| | Receptors, Opioid, kappa | 2 | 1994 | 9 | 0.050 |
Why?
| | Sample Size | 1 | 2004 | 124 | 0.050 |
Why?
| | Hydrocortisone | 5 | 2009 | 303 | 0.050 |
Why?
| | Complement Membrane Attack Complex | 1 | 2023 | 38 | 0.050 |
Why?
| | Histocompatibility Antigens Class II | 2 | 2010 | 365 | 0.050 |
Why?
| | Viral Envelope Proteins | 1 | 2024 | 97 | 0.050 |
Why?
| | Mental Recall | 2 | 1995 | 226 | 0.050 |
Why?
| | Aconitate Hydratase | 1 | 2003 | 14 | 0.050 |
Why?
| | Lymph Nodes | 3 | 2001 | 511 | 0.050 |
Why?
| | Chromatography, High Pressure Liquid | 4 | 2009 | 588 | 0.050 |
Why?
| | Pressure | 1 | 2004 | 221 | 0.050 |
Why?
| | Immunoglobulin G | 4 | 2002 | 901 | 0.050 |
Why?
| | Neck | 2 | 2001 | 107 | 0.050 |
Why?
| | Cell Culture Techniques | 1 | 2005 | 371 | 0.050 |
Why?
| | Adrenergic alpha-1 Receptor Antagonists | 1 | 2002 | 18 | 0.050 |
Why?
| | Adrenergic alpha-Antagonists | 1 | 2002 | 34 | 0.050 |
Why?
| | Adult | 4 | 2022 | 41087 | 0.050 |
Why?
| | Immobility Response, Tonic | 2 | 2013 | 6 | 0.050 |
Why?
| | Peripheral Nerves | 1 | 2003 | 73 | 0.050 |
Why?
| | Reflex | 2 | 1994 | 69 | 0.050 |
Why?
| | Superoxide Dismutase | 1 | 2004 | 307 | 0.040 |
Why?
| | Receptors, Cell Surface | 1 | 2004 | 371 | 0.040 |
Why?
| | Social Isolation | 1 | 2003 | 73 | 0.040 |
Why?
| | Antioxidants | 2 | 2022 | 544 | 0.040 |
Why?
| | Peroxynitrous Acid | 1 | 2022 | 11 | 0.040 |
Why?
| | Psychomotor Performance | 3 | 2015 | 329 | 0.040 |
Why?
| | Glycoproteins | 1 | 2024 | 356 | 0.040 |
Why?
| | NADPH Oxidase 2 | 1 | 2022 | 32 | 0.040 |
Why?
| | Death, Sudden | 1 | 1982 | 26 | 0.040 |
Why?
| | Nodose Ganglion | 2 | 1998 | 5 | 0.040 |
Why?
| | Real-Time Polymerase Chain Reaction | 2 | 2013 | 334 | 0.040 |
Why?
| | Lumbar Vertebrae | 1 | 2004 | 260 | 0.040 |
Why?
| | Myelin Sheath | 1 | 2023 | 166 | 0.040 |
Why?
| | Ventricular Fibrillation | 1 | 1982 | 63 | 0.040 |
Why?
| | T-Lymphocyte Subsets | 2 | 1995 | 416 | 0.040 |
Why?
| | Evoked Potentials, Auditory | 2 | 2011 | 187 | 0.040 |
Why?
| | Stem Cells | 1 | 2006 | 613 | 0.040 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2003 | 288 | 0.040 |
Why?
| | Nitric Oxide Synthase Type II | 1 | 2022 | 162 | 0.040 |
Why?
| | Interferon-gamma | 4 | 2001 | 781 | 0.040 |
Why?
| | Viral Proteins | 1 | 2024 | 351 | 0.040 |
Why?
| | Cell Line, Tumor | 2 | 2024 | 3545 | 0.040 |
Why?
| | Membrane Glycoproteins | 1 | 2024 | 495 | 0.040 |
Why?
| | Extracellular Vesicles | 1 | 2024 | 176 | 0.040 |
Why?
| | Reproducibility of Results | 2 | 2012 | 3416 | 0.040 |
Why?
| | Protein Conformation | 2 | 2018 | 916 | 0.040 |
Why?
| | Acute Disease | 2 | 2001 | 1038 | 0.040 |
Why?
| | NF-E2-Related Factor 2 | 1 | 2022 | 96 | 0.040 |
Why?
| | Epinephrine | 3 | 2002 | 160 | 0.040 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 2 | 2012 | 326 | 0.040 |
Why?
| | Phosphate-Binding Proteins | 1 | 2020 | 6 | 0.040 |
Why?
| | Injections | 2 | 2013 | 201 | 0.040 |
Why?
| | Organ Size | 1 | 2001 | 465 | 0.040 |
Why?
| | Aminopyridines | 2 | 2013 | 128 | 0.040 |
Why?
| | Evoked Potentials, Somatosensory | 2 | 2011 | 39 | 0.040 |
Why?
| | Rodentia | 1 | 2020 | 63 | 0.040 |
Why?
| | Amino Acid Sequence | 2 | 2016 | 2092 | 0.040 |
Why?
| | Crisis Intervention | 1 | 2020 | 34 | 0.040 |
Why?
| | Adjuvants, Immunologic | 2 | 2003 | 245 | 0.040 |
Why?
| | Receptors, Mineralocorticoid | 1 | 1999 | 11 | 0.040 |
Why?
| | Peritoneum | 1 | 2000 | 44 | 0.040 |
Why?
| | Depression | 2 | 2008 | 1575 | 0.040 |
Why?
| | Subarachnoid Space | 1 | 1999 | 8 | 0.040 |
Why?
| | Alzheimer Disease | 2 | 2020 | 641 | 0.040 |
Why?
| | Therapeutic Irrigation | 1 | 2000 | 69 | 0.040 |
Why?
| | Urocortins | 3 | 2004 | 24 | 0.040 |
Why?
| | Paresis | 1 | 1999 | 30 | 0.040 |
Why?
| | Motor Skills Disorders | 1 | 1999 | 23 | 0.040 |
Why?
| | Coronary Disease | 1 | 1982 | 380 | 0.040 |
Why?
| | Opioid Peptides | 1 | 1999 | 9 | 0.040 |
Why?
| | Sensitivity and Specificity | 1 | 2004 | 1998 | 0.040 |
Why?
| | Pyrimidines | 2 | 2003 | 532 | 0.040 |
Why?
| | Fluorescent Dyes | 2 | 2012 | 340 | 0.040 |
Why?
| | RNA, Double-Stranded | 1 | 2019 | 58 | 0.040 |
Why?
| | Immunity | 1 | 2000 | 141 | 0.040 |
Why?
| | alpha-MSH | 1 | 1998 | 6 | 0.040 |
Why?
| | Primary Cell Culture | 1 | 2019 | 173 | 0.040 |
Why?
| | Acute-Phase Reaction | 1 | 1998 | 37 | 0.040 |
Why?
| | Cerebellum | 1 | 2000 | 225 | 0.040 |
Why?
| | Glossopharyngeal Nerve | 1 | 1998 | 11 | 0.040 |
Why?
| | Anti-Bacterial Agents | 2 | 2008 | 1942 | 0.030 |
Why?
| | Immunologic Deficiency Syndromes | 2 | 2001 | 69 | 0.030 |
Why?
| | Optical Fibers | 1 | 2018 | 17 | 0.030 |
Why?
| | Protein Structure, Secondary | 1 | 2019 | 357 | 0.030 |
Why?
| | Fluorescent Antibody Technique | 1 | 1999 | 345 | 0.030 |
Why?
| | Limbic Lobe | 1 | 2018 | 3 | 0.030 |
Why?
| | Neuroanatomical Tract-Tracing Techniques | 1 | 2018 | 5 | 0.030 |
Why?
| | Stilbamidines | 1 | 2018 | 9 | 0.030 |
Why?
| | Injections, Epidural | 1 | 1998 | 29 | 0.030 |
Why?
| | Vaccines, Inactivated | 1 | 2018 | 71 | 0.030 |
Why?
| | Memory, Short-Term | 1 | 2020 | 276 | 0.030 |
Why?
| | Bromodeoxyuridine | 2 | 2009 | 74 | 0.030 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2005 | 665 | 0.030 |
Why?
| | Administration, Intranasal | 1 | 2018 | 95 | 0.030 |
Why?
| | Cell Proliferation | 3 | 2012 | 2502 | 0.030 |
Why?
| | Isonicotinic Acids | 1 | 1997 | 2 | 0.030 |
Why?
| | Receptors, GABA | 1 | 1997 | 13 | 0.030 |
Why?
| | Sucrose | 2 | 2008 | 113 | 0.030 |
Why?
| | Thermosensing | 2 | 1997 | 12 | 0.030 |
Why?
| | Oxytocics | 1 | 1997 | 15 | 0.030 |
Why?
| | Biguanides | 1 | 1997 | 10 | 0.030 |
Why?
| | Immunoassay | 1 | 2018 | 108 | 0.030 |
Why?
| | Amnesia, Anterograde | 2 | 2008 | 7 | 0.030 |
Why?
| | Pyrroles | 1 | 1999 | 222 | 0.030 |
Why?
| | Mannose | 1 | 2017 | 23 | 0.030 |
Why?
| | Baclofen | 1 | 1997 | 21 | 0.030 |
Why?
| | Analgesia, Epidural | 1 | 1997 | 38 | 0.030 |
Why?
| | Histocytochemistry | 1 | 1997 | 77 | 0.030 |
Why?
| | Skin Temperature | 2 | 1994 | 36 | 0.030 |
Why?
| | Phosphopyruvate Hydratase | 2 | 2007 | 26 | 0.030 |
Why?
| | Basolateral Nuclear Complex | 1 | 2016 | 11 | 0.030 |
Why?
| | RNA, Small Interfering | 1 | 2019 | 633 | 0.030 |
Why?
| | Transcriptional Activation | 1 | 1999 | 369 | 0.030 |
Why?
| | Extracellular Space | 2 | 2009 | 118 | 0.030 |
Why?
| | Jurkat Cells | 1 | 2016 | 115 | 0.030 |
Why?
| | Drug Evaluation, Preclinical | 1 | 1997 | 195 | 0.030 |
Why?
| | Nerve Net | 1 | 2000 | 286 | 0.030 |
Why?
| | Period Circadian Proteins | 1 | 2016 | 33 | 0.030 |
Why?
| | Receptors, Adrenergic, beta | 1 | 1996 | 58 | 0.030 |
Why?
| | Immunoglobulins | 1 | 1996 | 162 | 0.030 |
Why?
| | Psychological Tests | 1 | 2016 | 127 | 0.030 |
Why?
| | Hypercholesterolemia | 1 | 1996 | 95 | 0.030 |
Why?
| | Dentate Gyrus | 2 | 2006 | 41 | 0.030 |
Why?
| | Dysgammaglobulinemia | 1 | 1995 | 2 | 0.030 |
Why?
| | Anesthetics, Dissociative | 1 | 2016 | 49 | 0.030 |
Why?
| | IgG Deficiency | 1 | 1995 | 6 | 0.030 |
Why?
| | Optogenetics | 1 | 2016 | 103 | 0.030 |
Why?
| | Leukocytes | 2 | 2011 | 301 | 0.030 |
Why?
| | Saccharin | 1 | 1995 | 9 | 0.030 |
Why?
| | Animal Diseases | 1 | 2015 | 9 | 0.030 |
Why?
| | Leukocyte Common Antigens | 1 | 1995 | 86 | 0.030 |
Why?
| | Lymphocyte Culture Test, Mixed | 1 | 1995 | 49 | 0.030 |
Why?
| | 11-beta-Hydroxysteroid Dehydrogenase Type 1 | 1 | 2014 | 10 | 0.030 |
Why?
| | Capsaicin | 1 | 2015 | 30 | 0.030 |
Why?
| | 6-Cyano-7-nitroquinoxaline-2,3-dione | 1 | 1994 | 6 | 0.030 |
Why?
| | Chlorisondamine | 1 | 1994 | 3 | 0.030 |
Why?
| | Adrenal Medulla | 1 | 1994 | 10 | 0.030 |
Why?
| | Staphylococcal Infections | 1 | 1999 | 397 | 0.030 |
Why?
| | Monitoring, Physiologic | 2 | 1990 | 279 | 0.030 |
Why?
| | Blood Proteins | 1 | 1997 | 239 | 0.030 |
Why?
| | CD4 Antigens | 1 | 1995 | 136 | 0.030 |
Why?
| | Enkephalin, Ala(2)-MePhe(4)-Gly(5)- | 1 | 2014 | 11 | 0.030 |
Why?
| | Substance P | 1 | 1994 | 37 | 0.030 |
Why?
| | In Situ Hybridization | 2 | 2005 | 317 | 0.030 |
Why?
| | Weight Gain | 1 | 2018 | 562 | 0.030 |
Why?
| | Biphenyl Compounds | 1 | 1994 | 67 | 0.030 |
Why?
| | Monocytes | 1 | 1997 | 538 | 0.030 |
Why?
| | Decerebrate State | 1 | 1994 | 2 | 0.030 |
Why?
| | Ganglionectomy | 1 | 1994 | 2 | 0.030 |
Why?
| | Kupffer Cells | 1 | 1994 | 52 | 0.030 |
Why?
| | Ganglia, Sympathetic | 1 | 1994 | 14 | 0.030 |
Why?
| | Area Under Curve | 1 | 2015 | 335 | 0.030 |
Why?
| | Auditory Cortex | 1 | 1994 | 47 | 0.030 |
Why?
| | Valine | 1 | 2014 | 84 | 0.030 |
Why?
| | Catalysis | 1 | 2014 | 304 | 0.030 |
Why?
| | Basal Ganglia | 1 | 1994 | 60 | 0.020 |
Why?
| | Adiposity | 1 | 2018 | 533 | 0.020 |
Why?
| | Antidepressive Agents | 1 | 2016 | 235 | 0.020 |
Why?
| | Respiration | 1 | 2014 | 208 | 0.020 |
Why?
| | Biological Transport | 1 | 1995 | 424 | 0.020 |
Why?
| | Treatment Outcome | 3 | 2016 | 11821 | 0.020 |
Why?
| | Pregnancy | 3 | 2017 | 7230 | 0.020 |
Why?
| | Weight Loss | 2 | 2009 | 858 | 0.020 |
Why?
| | Infusion Pumps, Implantable | 1 | 2013 | 26 | 0.020 |
Why?
| | Receptors, Opioid, delta | 1 | 1992 | 10 | 0.020 |
Why?
| | Benzodiazepinones | 1 | 1992 | 18 | 0.020 |
Why?
| | Receptors, IgE | 1 | 2012 | 43 | 0.020 |
Why?
| | Anesthetics | 1 | 1993 | 100 | 0.020 |
Why?
| | Spodoptera | 1 | 2012 | 39 | 0.020 |
Why?
| | Phosphatidylcholines | 1 | 2013 | 131 | 0.020 |
Why?
| | MAP Kinase Kinase 4 | 1 | 2012 | 24 | 0.020 |
Why?
| | NF-KappaB Inhibitor alpha | 1 | 2012 | 50 | 0.020 |
Why?
| | Receptors, IgG | 1 | 2012 | 77 | 0.020 |
Why?
| | Gliosarcoma | 1 | 1992 | 8 | 0.020 |
Why?
| | Receptors, N-Methyl-D-Aspartate | 1 | 2014 | 233 | 0.020 |
Why?
| | Biological Assay | 1 | 2012 | 133 | 0.020 |
Why?
| | Lymphocyte Transfusion | 1 | 1992 | 20 | 0.020 |
Why?
| | Biophysics | 1 | 2012 | 75 | 0.020 |
Why?
| | Kinetics | 2 | 2006 | 1553 | 0.020 |
Why?
| | Virus Activation | 1 | 2012 | 97 | 0.020 |
Why?
| | Dimerization | 1 | 2012 | 174 | 0.020 |
Why?
| | Calcitonin Gene-Related Peptide | 1 | 2012 | 39 | 0.020 |
Why?
| | I-kappa B Proteins | 1 | 2012 | 75 | 0.020 |
Why?
| | Oxidation-Reduction | 1 | 2015 | 1075 | 0.020 |
Why?
| | Mitogen-Activated Protein Kinase Kinases | 1 | 2012 | 126 | 0.020 |
Why?
| | Azoles | 1 | 2011 | 4 | 0.020 |
Why?
| | Nitrobenzenes | 1 | 2011 | 15 | 0.020 |
Why?
| | Physical Exertion | 1 | 1992 | 204 | 0.020 |
Why?
| | Tetrodotoxin | 1 | 2011 | 40 | 0.020 |
Why?
| | Foot | 1 | 1992 | 109 | 0.020 |
Why?
| | Statistics as Topic | 1 | 2012 | 279 | 0.020 |
Why?
| | T-Cell Antigen Receptor Specificity | 1 | 2011 | 45 | 0.020 |
Why?
| | Protein Multimerization | 1 | 2012 | 201 | 0.020 |
Why?
| | Molecular Mimicry | 1 | 2011 | 36 | 0.020 |
Why?
| | Cell Differentiation | 1 | 2019 | 1982 | 0.020 |
Why?
| | Cardiopulmonary Resuscitation | 1 | 2015 | 334 | 0.020 |
Why?
| | Rotarod Performance Test | 1 | 2011 | 15 | 0.020 |
Why?
| | Biotin | 1 | 2011 | 32 | 0.020 |
Why?
| | Reflex, Righting | 1 | 2011 | 15 | 0.020 |
Why?
| | Pyramidal Tracts | 1 | 2011 | 30 | 0.020 |
Why?
| | Dextrans | 1 | 2011 | 83 | 0.020 |
Why?
| | Electrophysiology | 1 | 2011 | 219 | 0.020 |
Why?
| | Spectrometry, Fluorescence | 1 | 2011 | 165 | 0.020 |
Why?
| | Arginine Vasopressin | 1 | 1990 | 44 | 0.020 |
Why?
| | Interleukin-2 | 1 | 1992 | 434 | 0.020 |
Why?
| | Sphingosine | 1 | 2010 | 46 | 0.020 |
Why?
| | Protein Structure, Tertiary | 1 | 2012 | 834 | 0.020 |
Why?
| | Vasopressins | 1 | 1990 | 60 | 0.020 |
Why?
| | RNA Interference | 1 | 2012 | 472 | 0.020 |
Why?
| | Polyglycolic Acid | 1 | 2010 | 44 | 0.020 |
Why?
| | Lysophospholipids | 1 | 2010 | 80 | 0.020 |
Why?
| | PC12 Cells | 1 | 2009 | 42 | 0.020 |
Why?
| | Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2010 | 143 | 0.020 |
Why?
| | Dominance-Subordination | 1 | 2009 | 16 | 0.020 |
Why?
| | Serotonin Antagonists | 1 | 2009 | 33 | 0.020 |
Why?
| | Antimetabolites | 1 | 2009 | 21 | 0.020 |
Why?
| | Genes, fos | 1 | 2009 | 26 | 0.020 |
Why?
| | Esters | 1 | 2009 | 71 | 0.020 |
Why?
| | Vaccination | 1 | 2018 | 1449 | 0.020 |
Why?
| | Temperature | 1 | 1992 | 635 | 0.020 |
Why?
| | Drinking | 2 | 1999 | 44 | 0.020 |
Why?
| | Adaptation, Physiological | 2 | 2003 | 568 | 0.020 |
Why?
| | Aldehydes | 1 | 2009 | 140 | 0.020 |
Why?
| | Myelin-Associated Glycoprotein | 1 | 2008 | 7 | 0.020 |
Why?
| | Electromyography | 1 | 1991 | 428 | 0.020 |
Why?
| | Microscopy, Confocal | 1 | 2009 | 322 | 0.020 |
Why?
| | Myelin Proteins | 1 | 2008 | 45 | 0.020 |
Why?
| | Biological Products | 1 | 2012 | 258 | 0.020 |
Why?
| | Particle Size | 1 | 2010 | 386 | 0.020 |
Why?
| | Lactic Acid | 1 | 2010 | 295 | 0.020 |
Why?
| | GABA-A Receptor Antagonists | 1 | 2008 | 19 | 0.020 |
Why?
| | Exercise Test | 1 | 2011 | 637 | 0.020 |
Why?
| | Action Potentials | 1 | 2011 | 500 | 0.020 |
Why?
| | Parietal Lobe | 1 | 2008 | 62 | 0.020 |
Why?
| | Sequence Analysis, DNA | 1 | 2011 | 771 | 0.020 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 1995 | 1150 | 0.020 |
Why?
| | Endothelium, Vascular | 1 | 1995 | 952 | 0.020 |
Why?
| | Chemical and Drug Induced Liver Injury | 1 | 2009 | 138 | 0.020 |
Why?
| | Immunotherapy, Adoptive | 1 | 1992 | 356 | 0.020 |
Why?
| | Naproxen | 1 | 2007 | 21 | 0.020 |
Why?
| | Bronchodilator Agents | 1 | 2008 | 186 | 0.020 |
Why?
| | G-Protein-Coupled Receptor Kinase 2 | 1 | 2007 | 9 | 0.020 |
Why?
| | Endotoxemia | 1 | 2007 | 85 | 0.020 |
Why?
| | Immunologic Memory | 1 | 2009 | 369 | 0.020 |
Why?
| | Mesentery | 2 | 1998 | 44 | 0.020 |
Why?
| | Molecular Sequence Data | 1 | 2011 | 2838 | 0.020 |
Why?
| | Anticonvulsants | 1 | 2009 | 253 | 0.020 |
Why?
| | Heart Rate | 1 | 1990 | 846 | 0.020 |
Why?
| | Gyrus Cinguli | 1 | 2006 | 98 | 0.010 |
Why?
| | Mass Spectrometry | 1 | 2009 | 729 | 0.010 |
Why?
| | Microtubule-Associated Proteins | 1 | 2007 | 187 | 0.010 |
Why?
| | Thiocarbamates | 1 | 2005 | 6 | 0.010 |
Why?
| | Bacterial Proteins | 1 | 2012 | 980 | 0.010 |
Why?
| | Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2005 | 49 | 0.010 |
Why?
| | Tyrosine 3-Monooxygenase | 1 | 2005 | 72 | 0.010 |
Why?
| | Locus Coeruleus | 1 | 2005 | 25 | 0.010 |
Why?
| | Phenotype | 2 | 2009 | 3206 | 0.010 |
Why?
| | Estrous Cycle | 1 | 2005 | 21 | 0.010 |
Why?
| | Proline | 1 | 2005 | 79 | 0.010 |
Why?
| | 5,7-Dihydroxytryptamine | 1 | 2004 | 2 | 0.010 |
Why?
| | Pro-Opiomelanocortin | 1 | 2004 | 20 | 0.010 |
Why?
| | Aminoglutethimide | 1 | 2004 | 4 | 0.010 |
Why?
| | Metyrapone | 1 | 2004 | 5 | 0.010 |
Why?
| | Serotonin Agents | 1 | 2004 | 8 | 0.010 |
Why?
| | Motor Cortex | 1 | 2005 | 66 | 0.010 |
Why?
| | Rats, Mutant Strains | 1 | 2004 | 19 | 0.010 |
Why?
| | Reptilian Proteins | 1 | 2004 | 3 | 0.010 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2009 | 778 | 0.010 |
Why?
| | Group II Phospholipases A2 | 1 | 2004 | 10 | 0.010 |
Why?
| | Receptors, Leptin | 1 | 2004 | 25 | 0.010 |
Why?
| | Electrochemistry | 1 | 2004 | 69 | 0.010 |
Why?
| | Cyclooxygenase Inhibitors | 1 | 2004 | 82 | 0.010 |
Why?
| | Transcription Factors | 1 | 2012 | 1730 | 0.010 |
Why?
| | Catecholamines | 1 | 2004 | 88 | 0.010 |
Why?
| | Concanavalin A | 1 | 2003 | 72 | 0.010 |
Why?
| | Apoptosis | 1 | 2012 | 2439 | 0.010 |
Why?
| | Serotonin 5-HT1 Receptor Antagonists | 1 | 2003 | 2 | 0.010 |
Why?
| | Cholesterol, VLDL | 1 | 2003 | 5 | 0.010 |
Why?
| | Electrolysis | 1 | 2003 | 2 | 0.010 |
Why?
| | Immobilization | 1 | 2003 | 54 | 0.010 |
Why?
| | Blood Pressure | 1 | 1990 | 1765 | 0.010 |
Why?
| | HIV Infections | 1 | 1999 | 3215 | 0.010 |
Why?
| | Sleep | 1 | 2011 | 896 | 0.010 |
Why?
| | Nanoparticles | 1 | 2010 | 523 | 0.010 |
Why?
| | Sepsis | 1 | 2010 | 669 | 0.010 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2011 | 2240 | 0.010 |
Why?
| | Oxathiins | 1 | 2002 | 1 | 0.010 |
Why?
| | Cholesterol, HDL | 1 | 2003 | 201 | 0.010 |
Why?
| | gamma-Aminobutyric Acid | 1 | 2004 | 195 | 0.010 |
Why?
| | Prostheses and Implants | 1 | 1984 | 137 | 0.010 |
Why?
| | Drug Resistance | 1 | 2003 | 145 | 0.010 |
Why?
| | Brain Neoplasms | 1 | 1992 | 1325 | 0.010 |
Why?
| | Physical Examination | 1 | 2003 | 237 | 0.010 |
Why?
| | Cell Division | 1 | 2003 | 736 | 0.010 |
Why?
| | Aniline Compounds | 1 | 2003 | 120 | 0.010 |
Why?
| | Gelatin Sponge, Absorbable | 1 | 2001 | 6 | 0.010 |
Why?
| | Wallerian Degeneration | 1 | 2001 | 4 | 0.010 |
Why?
| | Neuropsychological Tests | 1 | 2006 | 1149 | 0.010 |
Why?
| | Tachycardia | 1 | 1982 | 58 | 0.010 |
Why?
| | Dopamine Uptake Inhibitors | 1 | 2002 | 59 | 0.010 |
Why?
| | Epitopes | 1 | 2003 | 479 | 0.010 |
Why?
| | Cholesterol, LDL | 1 | 2003 | 363 | 0.010 |
Why?
| | Emotions | 1 | 2006 | 559 | 0.010 |
Why?
| | Muscle Denervation | 1 | 2001 | 8 | 0.010 |
Why?
| | Lymphocyte Count | 1 | 2001 | 167 | 0.010 |
Why?
| | Immunoglobulin Isotypes | 1 | 2001 | 36 | 0.010 |
Why?
| | Organ Specificity | 1 | 2002 | 307 | 0.010 |
Why?
| | Luminescent Measurements | 1 | 2001 | 75 | 0.010 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2006 | 902 | 0.010 |
Why?
| | Diagnostic Imaging | 1 | 2004 | 340 | 0.010 |
Why?
| | Spironolactone | 1 | 2001 | 40 | 0.010 |
Why?
| | Hypertrophy | 1 | 2001 | 127 | 0.010 |
Why?
| | Long-Term Potentiation | 1 | 2002 | 206 | 0.010 |
Why?
| | Pregnancy Complications, Infectious | 1 | 2005 | 438 | 0.010 |
Why?
| | Thymus Gland | 1 | 2001 | 310 | 0.010 |
Why?
| | Gene Expression Profiling | 1 | 2006 | 1792 | 0.010 |
Why?
| | Periaqueductal Gray | 1 | 1999 | 37 | 0.010 |
Why?
| | Peritoneal Cavity | 1 | 1998 | 30 | 0.010 |
Why?
| | Prognosis | 1 | 2007 | 4351 | 0.010 |
Why?
| | Rats, Long-Evans | 1 | 1998 | 126 | 0.010 |
Why?
| | Administration, Oral | 1 | 2001 | 872 | 0.010 |
Why?
| | Hydroxyindoleacetic Acid | 1 | 1998 | 24 | 0.010 |
Why?
| | CD4 Lymphocyte Count | 1 | 1998 | 280 | 0.010 |
Why?
| | Follow-Up Studies | 1 | 2007 | 5439 | 0.010 |
Why?
| | Flow Cytometry | 1 | 2001 | 1163 | 0.010 |
Why?
| | Butoxamine | 1 | 1996 | 1 | 0.010 |
Why?
| | Atenolol | 1 | 1996 | 8 | 0.010 |
Why?
| | Receptors, Adrenergic, beta-1 | 1 | 1996 | 24 | 0.010 |
Why?
| | Propranolol | 1 | 1996 | 44 | 0.010 |
Why?
| | Receptors, Adrenergic, beta-2 | 1 | 1996 | 36 | 0.010 |
Why?
| | Fatty Acids, Nonesterified | 1 | 1996 | 154 | 0.010 |
Why?
| | Diazepam | 1 | 1995 | 32 | 0.010 |
Why?
| | Adrenal Cortex Hormones | 1 | 1999 | 486 | 0.010 |
Why?
| | Anti-Anxiety Agents | 1 | 1995 | 46 | 0.010 |
Why?
| | Adrenergic beta-Antagonists | 1 | 1996 | 253 | 0.010 |
Why?
| | Electrodes, Implanted | 1 | 1995 | 114 | 0.010 |
Why?
| | Cytological Techniques | 1 | 1995 | 25 | 0.010 |
Why?
| | Nylons | 1 | 1995 | 25 | 0.010 |
Why?
| | Jugular Veins | 1 | 1994 | 41 | 0.010 |
Why?
| | Prospective Studies | 1 | 2007 | 8123 | 0.010 |
Why?
| | Horseradish Peroxidase | 1 | 1994 | 26 | 0.010 |
Why?
| | Methoxyflurane | 1 | 1993 | 2 | 0.010 |
Why?
| | Chloral Hydrate | 1 | 1993 | 3 | 0.010 |
Why?
| | Halothane | 1 | 1993 | 8 | 0.010 |
Why?
| | Pentobarbital | 1 | 1993 | 17 | 0.010 |
Why?
| | Xylazine | 1 | 1993 | 16 | 0.010 |
Why?
| | CD4-CD8 Ratio | 1 | 1992 | 23 | 0.010 |
Why?
| | Cholesterol, Dietary | 1 | 1992 | 15 | 0.010 |
Why?
| | Cold Temperature | 1 | 1993 | 208 | 0.010 |
Why?
| | Neoplasm Transplantation | 1 | 1992 | 238 | 0.010 |
Why?
| | Lymphocyte Activation | 1 | 1995 | 1137 | 0.010 |
Why?
| | T-Lymphocytes, Cytotoxic | 1 | 1992 | 180 | 0.010 |
Why?
| | Obesity | 1 | 2004 | 3131 | 0.010 |
Why?
| | Tumor Cells, Cultured | 1 | 1992 | 882 | 0.000 |
Why?
| | Dietary Fats | 1 | 1992 | 307 | 0.000 |
Why?
| | Actuarial Analysis | 1 | 1984 | 15 | 0.000 |
Why?
| | Adolescent | 1 | 1982 | 22557 | 0.000 |
Why?
| | Aged | 1 | 1982 | 26432 | 0.000 |
Why?
| | Recurrence | 1 | 1984 | 1133 | 0.000 |
Why?
| | Electrocardiography | 1 | 1984 | 667 | 0.000 |
Why?
| | Middle Aged | 1 | 1982 | 36619 | 0.000 |
Why?
|
|
Watkins's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|